O'Daniel J, Lucas J, Deverka P, Ermentrout D, Silvey G, Lobach D F, Haga S B
Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA.
Public Health Genomics. 2010;13(1):48-54. doi: 10.1159/000217795. Epub 2009 May 4.
The successful integration of pharmacogenetic (PGx) testing into clinical care will require attention to patient attitudes. In this study, we aimed to identify the major reasons why patients would or would not consider PGx testing and whether these factors differed by race, socioeconomic and insurance status, and medical history.
We developed and conducted a survey within the adult patient population of the Duke Family Medicine Center.
Of 75 completed surveys (65% African-American), 77% indicated they were 'very likely' or 'somewhat likely' to take a PGx test. Respondents who had experienced a side effect were significantly more likely to indicate they would take a PGx test and expressed greater interest in learning more about testing than those who had not. Drug safety and effectiveness were the major reasons to have PGx testing. Privacy concerns and lack of insurance coverage for testing were the major reasons to decline testing.
We found no differences in interest in PGx tests by race or socioeconomic status, but found stronger interest from those with a history of side effects and private insurance. While the overall support of PGx testing is encouraging, greater reassurance of medical privacy and development of educational resources are needed.
将药物遗传学（PGx）检测成功整合到临床护理中需要关注患者的态度。在本研究中，我们旨在确定患者愿意或不愿意考虑PGx检测的主要原因，以及这些因素是否因种族、社会经济和保险状况以及病史而异。
我们在杜克家庭医学中心的成年患者群体中开展并进行了一项调查。
在75份完成的调查问卷中（65%为非裔美国人），77%的人表示他们“非常有可能”或“ somewhat有可能”进行PGx检测。经历过副作用的受访者表示他们更有可能进行PGx检测，并且比未经历过副作用的受访者对了解更多检测信息表现出更大的兴趣。药物安全性和有效性是进行PGx检测的主要原因。隐私担忧和检测缺乏保险覆盖是拒绝检测的主要原因。
我们发现种族或社会经济地位对PGx检测的兴趣没有差异，但发现有副作用病史和私人保险的人兴趣更强。虽然对PGx检测的总体支持令人鼓舞，但仍需要更大程度地保证医疗隐私并开发教育资源。
